Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mean improvement in Ct 26% Improvement Relative Risk Viral load reduction < 3.. 38% c19early.org/n Silva et al. NCT04463264 Nitazoxanide RCT EARLY TREATMENT Is early treatment with nitazoxanide beneficial for COVID-19? RCT 36 patients in Argentina Improved viral clearance with nitazoxanide (not stat. sig., p=0.36) Silva et al., medRxiv, doi:10.1101/2021.03.03.21252509 Favors nitazoxanide Favors control
Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study
Silva et al., medRxiv, doi:10.1101/2021.03.03.21252509 (Preprint), NCT04463264 (history)
Silva et al., Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled,.., medRxiv, doi:10.1101/2021.03.03.21252509 (Preprint), NCT04463264
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT with 23 nitazoxanide and 13 control patients showing significantly more patients achieved over 35% reduction in viral load from baseline. NCT04463264 (history).
relative mean improvement in Ct, 26.5% better, RR 0.74, p = 0.36, treatment 23, control 13.
risk of viral load reduction < 35% at day 7, 38.3% lower, RR 0.62, p = 0.08, treatment 12 of 23 (52.2%), control 11 of 13 (84.6%), NNT 3.1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Silva et al., 5 Mar 2021, Single Blind Randomized Controlled Trial, Argentina, preprint, 11 authors, trial NCT04463264 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.03.21252509; this version posted March 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Title: Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study. Authors: Marcelo Silva1, Andrés Espejo1, María L Pereyra1, Martín Lynch1, Marcos Thompson1, Hernán Taconelli2, Patricia Baré3, Matías J Pereson3, Marcelo Garbini4, Pablo Crucci4, Diego Enriquez4. Affiliations: 1Unidad de Hepatología y Trasplante Hepático, Hospital Universitario Austral, Pilar, Argentina. 2Sanatorio Nuestra Señora del Pilar, Ciudadela, Argentina. 3IIHEMA, IMEX-CONICET, Academia Nacional de Medicina. 4Departamento de Investigación Clínica, Laboratorios Roemmers. Corresponding author: Prof. Marcelo Silva, MD. Director de la Unidad de Hepatología y Trasplante Hepático, Hospital Universitario Austral, Pilar, Argentina Av. J. D. Perón 1500 (1629). Derqui, Provincia de Buenos Aires, Argentina. e-mail: msilva@cas.austral.edu.ar Abstract: The fast spread of COVID-19 has overcrowded Public Health Systems facilities in major countries due to the large number of seriously ill patients, particularly those requiring admission to intensive care units. Reducing viral load, along with other recommended epidemiological measures, such as social distancing and home confinement, can in time significantly help to reduce the infection R0 (Basic Reproductive Rate) and then mitigate disease burden. Early negativization or otherwise reduction of the viral load can potentially diminish disease severity, resulting in a better-controlled public health response, avoiding collapse of healthcare systems. Nitazoxanide, a widely used thiazolide approved by the FDA as an antiparasitic drug, also approved in Brazil for Norovirus and Rotavirus treatments, has an excellent safety record for a variety of indications. Nitazoxanide exhibits activity in vitro against MERS-CoV and other coronaviruses; and a specific antiviral effect (in micro molar doses) against SARS-CoV-2. The objective of this study was to evaluate the efficacy and safety of Nitazoxanide in reducing the SARS-COV 2 viral load within 7 days of treatment in respiratory samples from COVID-19-infected patients with mild to moderate disease, compared to placebo. An interim analysis showed that the ratio of patients with a viral load reduction ≥ 35% from baseline up to day 7 of treatment was significantly greater for Nitazoxanide compared to placebo (47.8% vs. 15.4%; Δ 34.6%; 95% CI: 64.7; 4.6: p = 0.037). 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.03.21252509; this version posted March 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Key words: Nitazoxanide, COVID-19, viral load, antiviral, SARS-Cov-2. KEY POINTS State of the Art:  Different studies conclude that viral load (VL) would correlate with morbidity, mortality and contagiousness of..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit